Projects per year
Personal profile
Biography
Dr Azad is an early-career medical oncologist and translational researcher with a special interest in genitourinary malignancies.
After completing his medical oncology training and a PhD in cell biology in Melbourne, Dr Azad moved to the British Columbia (BC) Cancer Agency and Vancouver Prostate Centre, Canada for a 2-year fellowship under the supervision of Professor Kim Chi, an internationally renowned prostate cancer researcher.
At BC Cancer Agency, Dr Azad played a major role in the development of five investigator-initiated clinical trials, was actively involved in outcomes research, and led pioneering studies centred on genomic profiling of circulating cell-free DNA in advanced prostate cancer patients developing resistance to next-generation hormonal agents. The significance of Dr Azad's work with cell-free DNA was recognized by four highly prestigious Merit Awards from the American Society of Clinical Oncology and first author publications in Clinical Cancer Research and JAMA Oncology.
Dr Azad has a strong academic record including 64 publications, a patent, 11 oral presentations at national and international meetings, Poster Highlights Sessions at the 2014 and 2015 ASCO Annual Meeting, 22 competitive prizes and awards and over $4.5M in competitive funding.
In November 2015, Dr Azad commenced appointments at Monash University and Monash Health, where he is leading a clinical and translational prostate cancer research program. His ongoing research centres on circulating biomarker analysis in advanced prostate cancer patients (supported by an NHMRC Project Grant) and the predictive utility of non-coding RNA for BET inhibition in prostate cancer (supported by a Victorian Cancer Agency Translational Research Project Grant). He is also actively involved in clinical trials and notably is the lead Australian investigator for two clinical trials in advanced prostate cancer patients.
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2013 2023
New combination therapies for castration-resistant prostat e cancer
Lawrence, M., Risbridger, G., Azad, A. & Taylor, R.
15/02/19 → 14/02/23
Project: Research
Application of a multi-gene prostate circulating tumour DNA (ctDNA) panel in men with metastatic hormone- sensitive prostate cancer (mHSPC)
Southey, M., Kwan, E., Fettke, H. C. & Azad, A.
4/09/18 → 3/09/19
Project: Research
Novel targeting of therapy-resistant prostate cancer cells.
Taylor, R., Risbridger, G., Azad, A. & Nim, H.
1/01/18 → 31/12/20
Project: Research
A novel strategy for targeting castrate-resistant prostate cancer
Risbridger, G., Tilley, W. D., Furic, L., Sandhu, S. K., Azad, A., Selth, L. & Lawrence, M.
National Health & Medical Research Council (NHMRC)
1/01/18 → 31/12/21
Project: Research
The PRECISE assay: Personalised medicine for cancer patients using next-generation sequencing
To, S., Azad, A., Shortt, J., Wei, A., Shackleton, M. & Kenealy, M.
1/12/17 → 1/12/20
Project: Research
Research Output 2006 2019
Cell-free DNA in cancer: current insights
Fettke, H., Kwan, E. M. & Azad, A. A., 15 Feb 2019, In : Cellular Oncology. 42, 1, p. 13-28 16 p.Research output: Contribution to journal › Review Article › Research › peer-review
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer
Kwan, E. M., Fettke, H., Docanto, M. M., To, S. Q., Bukczynska, P., Mant, A., Pook, D., Ng, N., Graham, L. J. K., Mangiola, S., Segelov, E., Mahon, K., Davis, I. D., Parente, P., Pezaro, C., Todenhöfer, T., Horvath, L. G. & Azad, A. A., 15 May 2019, (Accepted/In press) In : European Urology Focus. 8 p.Research output: Contribution to journal › Article › Research › peer-review
Where to Next for Theranostics in Prostate Cancer?
Murphy, D. G., Sathianathen, N., Hofman, M. S., Azad, A. & Lawrentschuk, N., 1 Mar 2019, In : European Urology Oncology. 2, 2, p. 163-165 3 p.Research output: Contribution to journal › Editorial › Other › peer-review
Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC)
Kwan, E. M., To, S. Q. G., Fettke, H. C., Docanto, M., Bukczynska, P., Mant, A. M., Pook, D. W., Ng, N., Graham, L. J. K., Segelov, E., Mahon, K. L., Davis, I., Parente, P., Pezaro, C., Horvath, L. G. & Azad, A., 1 Mar 2019, In : Journal of Clinical Oncology. 37, 7 Suppl, p. 188 1 p.Research output: Contribution to journal › Meeting Abstract › Other › peer-review
A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate
Khalaf, D. J., Avilés, C. M., Azad, A. A., Sunderland, K., Todenhöfer, T., Eigl, B. J., Finch, D., Le, L., Atwell, A., Keith, B., Kollmannsberger, C. & Chi, K. N., 1 Feb 2018, In : Canadian Urological Association. 12, 2, p. E47-E52 6 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access
File